Paper Details

  1. Home
  2. Paper Details

Review article: mild to moderate Crohn's disease--defining the basis for a new treatment algorithm.

Author: FeaganB G, SandbornW J

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Meta-AnalysisA statistical technique that integrates the results of multiple studies to draw more general conclusions about a particular issue.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Overview

This review evaluated the effectiveness and safety of common treatments for mild to moderate Crohn's disease. Sulfasalazine showed modest benefits when the disease was limited to the colon. Mesalamine did not offer a clear advantage over placebo for active Crohn's disease. Conventional corticosteroids effectively induced remission but had significant side effects. Budesonide was as effective as conventional steroids but with fewer side effects. Antibiotics did not consistently show effectiveness. Based on these findings, the review suggests using budesonide for patients with ileal or right-sided colon involvement, sulfasalazine for those with colon-only disease, and conventional steroids for high activity, budesonide failure, or left-sided disease with sulfasalazine intolerance.
Paper Details　
Original Abstract of the Article :
Previously, clinicians have had few choices in treating mild to moderate Crohn's disease. They currently treat these Crohn's disease patients with oral mesalamine and antibiotics. This treatment approach is based on the safety of these agents, and the perception that they are effective. This percept...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1046/j.1365-2036.2003.01661.x

データ提供：米国国立医学図書館（NLM）

A New Treatment Algorithm for Crohn's Disease

Crohn's disease, a chronic inflammatory bowel disease, is a challenging condition to manage. Imagine it like a stubborn desert sandstorm – it takes persistence and the right tools to find relief. This study aims to shed light on the most effective treatments for mild to moderate Crohn's disease. It delves into the available evidence for various medications, including mesalamine, sulfasalazine, budesonide, and antibiotics, and proposes a more evidence-based approach to treatment.

Navigating the Sands of Treatment Options

The researchers meticulously reviewed clinical trials to determine the efficacy and safety of different treatments. They discovered that budesonide, a corticosteroid, stands out as a promising treatment option for inducing remission, offering similar efficacy to traditional steroids with fewer adverse effects. This is like discovering a hidden oasis in the desert – a more effective and gentler way to find relief.

Treating Crohn's with a New Compass

The study proposes a new treatment algorithm, recommending budesonide for patients with ileal and/or right colonic involvement, sulfasalazine for those with colon-limited disease, and conventional steroids for those with higher disease activity or those who haven't responded to other treatments. It's like having a new compass to guide you through the desert of Crohn's disease, offering a more targeted and effective approach to treatment.

Dr. Camel's Conclusion

This study offers a clear and evidence-based approach to treating mild to moderate Crohn's disease, emphasizing the importance of choosing the right treatment for the right patient. It's a valuable tool for navigating the challenges of Crohn's disease, providing patients and their healthcare providers with a roadmap to better management and potential remission.

Date :
  1. Date Completed 2003-10-07
  2. Date Revised 2019-09-01
Further Info :

Pubmed ID

12895211

DOI: Digital Object Identifier

10.1046/j.1365-2036.2003.01661.x

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.